AstraZeneca Plc, whose setbacks in drug development have made the stock the cheapest among the largest pharmaceutical companies, is turning to RNA technology to boost its chances of discovering new therapies.
AstraZeneca Plc’s head of research and development and its most senior executive for worldwide sales and marketing activities are leaving the company after Chief Executive Officer Pascal Soriot eliminated their jobs.
AstraZeneca Plc named Martin Mackay to lead research and development, hiring a Pfizer Inc. executive for the second time this year as the U.K. drugmaker seeks to replace revenue it’s losing to generic competitors.
AstraZeneca Plc’s $1.26 billion purchase of Ardea Biosciences Inc., its biggest acquisition in five years, may be the first in a series of deals for the company as it tries to counter looming generic competition.
David Brennan couldn’t sit still. During a meal of beef and potatoes at AstraZeneca Plc’s drug research center near Stockholm in October, Brennan, the company’s chief executive officer, grilled six drug-development managers over a concern raised by a laboratory scientist.
AstraZeneca Plc fell the most in more than two years in London trading after the U.K. drugmaker failed to win U.S. approval for a new blood thinner to rival Plavix, the world’s second-best selling drug.